TGFB1 and Hyperglycemia: EVs derived from bone-marrow and human liver stem cells, were shown to transfer miR-222 to MCs and downregulate TGF-β and miR21 in an in vitro model of MCs hyperglycaemia, thus serving as potential therapeutic agents to protect MCs from hyperglycaemia-induced damage and collagen production (Gallo et al., 2016).